Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach.
Level 5 - mechanism / opinion, no new human data
Narrative opinion review without systematic review methodology or original data
PubMed 42626011 · doi:10.5527/wjn.120295
What was done
This is an opinion review synthesizing literature on disease-modifying strategies in diabetic kidney disease, focusing on the mechanistic rationale and clinical trial evidence for combining finerenone (a non-steroidal mineralocorticoid receptor antagonist) with dapagliflozin (an SGLT-2 inhibitor) and telmisartan (an angiotensin II receptor blocker).
What was found
No quantitative findings, sample sizes, or numerical effect sizes are reported in the abstract. The authors summarize that finerenone and SGLT-2 inhibitors each independently improve renal and cardiovascular outcomes in type 2 diabetes, suggesting that their combined use with standard renin-angiotensin system blockade offers complementary therapeutic benefits.
Why it matters
It highlights a multi-target pharmacological framework using combined MRA and SGLT-2 inhibition alongside standard renin-angiotensin blockade to slow diabetic nephropathy progression.
Limits
This is an opinion review offering qualitative synthesis rather than primary empirical data or a systematic review with meta-analysis. The abstract provides no original patient data, comparative effect estimates, or numerical measures of proteinuria reduction.
Cited by
- supports Diabetes and high blood sugar are the number one cause of kidney damage.